---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-025989"
form_type: "8-K"
ticker: "PMHS"
cik: "0001265521"
company_name: "Polomar Health Services, Inc."
filed_at: "2025-08-29T23:59:59+00:00"
generated_at: "2026-05-17T09:09:40.387277+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Polomar Health partners with ForHumanity; $750K guaranteed for exclusive marketing of inhalable drugs

## Summary
- Guaranteed payments of $750K; $200K already received, with remaining $500K due by Oct 31, 2025.
- Exclusivity for inhalable sildenafil and eletriptan through March 31, 2026, extendable via revenue milestones (e.g., $1.5M by Mar 31, 2026; $3M by Jun 30, 2026; $8M for FY 2026).
- Initial term 42 months (Mar 17, 2025 – Sep 16, 2028) with automatic renewals if average annual revenues meet $3M (first renewal) and $6M (second renewal).
- Fulfillment by Polomar Specialty Pharmacy; IG4 handles account management; additional $50K advance due by Sep 15, 2025.
- Product pricing capped at 3% annual increase during initial term; Polomar must reserve 8,000 kits of each product for ForHumanity.

## SEC filing metadata
- accession: 0001641172-25-025989
- form_type: 8-K
- ticker: PMHS
- cik: 0001265521
- company_name: Polomar Health Services, Inc.
- filed_at: 2025-08-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1265521/000164117225025989/0001641172-25-025989-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1265521/000164117225025989/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-025989
- JSON: https://secwatch.observer/filing/0001641172-25-025989.json
- Plain text: https://secwatch.observer/filing/0001641172-25-025989.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.